Antiviral

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

By

Women with a high hepatitis B viral load who receive tenofovir during pregnancy have a significantly reduced risk for passing on the virus to their child, without an increase in the risk of adverse events.

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

By

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Abnormal Bone Metabolism With Tenofovir for HBV Infection

By

Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

By

Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

By

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

By

The 8-week regimen of LDV/SOF for HCV genotype 1 induced sustained virologic response at 12 weeks in nearly all patients treated.

Sign Up for Free e-newsletters